Pages that link to "Q33699572"
Jump to navigation
Jump to search
The following pages link to Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide (Q33699572):
Displaying 26 items.
- MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study (Q34166477) (← links)
- Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study. (Q34572229) (← links)
- Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. (Q34722450) (← links)
- Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma (Q35538698) (← links)
- MGMT testing allows for personalised therapy in the temozolomide era. (Q35827916) (← links)
- Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma (Q35942167) (← links)
- Personalized treatment strategies in glioblastoma: MGMT promoter methylation status (Q37221207) (← links)
- Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance (Q37964451) (← links)
- Temozolomide dosing regimens for glioma patients (Q37995906) (← links)
- MGMT testing--the challenges for biomarker-based glioma treatment (Q38218848) (← links)
- Predictive biomarkers investigated in glioblastoma. (Q38237337) (← links)
- Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference (Q38786758) (← links)
- Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme. (Q39772040) (← links)
- Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma (Q40892270) (← links)
- Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis (Q42364418) (← links)
- Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy (Q42623558) (← links)
- A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime (Q44141105) (← links)
- The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis (Q45835773) (← links)
- The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis (Q46915446) (← links)
- Personalized surgical therapy (Q48365755) (← links)
- Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients (Q48797026) (← links)
- The validity of EORTC GBM prognostic calculator on survival of GBM patients in the West of Scotland (Q48944191) (← links)
- Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). (Q55052526) (← links)
- The surgical perspective in precision treatment of diffuse gliomas (Q64114259) (← links)
- Case-Based Review: newly diagnosed glioblastoma (Q92446802) (← links)
- Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma (Q92799371) (← links)